Stocks to Watch: Horizon Pharma Inc (NASDAQ:HZNP), Avanir Pharmaceuticals (NASDAQ:AVNR), Catalyst Pharmaceutical Partners (NASDAQ:CPRX), Supernus Pharmaceuticals (NASDAQ:SUPN)

Specialist pharmaceutical company Horizon Pharma Inc (NASDAQ:HZNP) revealed on Thursday the receipt of Notice of Allowance for US Patent Application 13/713,528 entitled “Delayed-Release Tablet with Defined Core Geometry” that covers its US approved product RAYOS. Horizon Pharma Inc (NASDAQ:HZNP) stock performance was -7.89% in last session and finished the day at $12.02. Traded volume was 3.88million shares in the last session and the average volume of the stock remained 2.63million shares. Horizon Pharma Inc (NASDAQ:HZNP) insider ownership is 0.60%.

Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) is +0.0004 at $3.29, with 703,841 shares traded. As reported by Zacks, the current mean recommendation for AVNR is in the “buy range”. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) dropped -9.37 percent to $ 3.29 Friday on volume of 2.78million shares. The intra-day range of the stock was $3.28 to $3.69. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) has a market capitalization of $501.05million.

Pharmaceutical company Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) revealed on Tuesday the completion of its public offering at an offering price of USD2.21 per share. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)’s stock on Apr 11, 2014 reported a decrease of -7.21% to the closing price of $2.06. Its fifty two weeks range is $0.46-$3.65. The total market capitalization recorded $134.87million. The overall volume in the last trading session was million shares. In its share capital, CPRX has 65.49million outstanding shares.

Investors considering a purchase of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares, but tentative about paying the going market price of $9.29/share, might benefit from considering selling puts among the alternative strategies at their disposal. On Friday, shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) dropped -6.38% to close the day at $7.93. Company return on investment (ROI) is -105.30% and its monthly performance is recorded as -18.75%. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) quarterly revenue growth is -5.37%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone